<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Sk Biopharmaceuticals Co Ltd — News on 6ix</title>
<link>https://6ix.com/company/sk-biopharmaceuticals-co-ltd</link>
<description>Latest news and press releases for Sk Biopharmaceuticals Co Ltd on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 06 Apr 2026 12:04:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/sk-biopharmaceuticals-co-ltd" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo683630d978dffbe2df147ca8.webp</url>
<title>Sk Biopharmaceuticals Co Ltd</title>
<link>https://6ix.com/company/sk-biopharmaceuticals-co-ltd</link>
</image>
<item>
<title>SK Life Science, Inc. to Present New Data and Epilepsy Insights at the 2026 American Academy of Neurology Annual Meeting</title>
<link>https://6ix.com/company/sk-biopharmaceuticals-co-ltd/news/sk-life-science-inc-to-present-new-data-and-epilepsy-insights-at-the-2026-american-academy-of-neurology-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/sk-biopharmaceuticals-co-ltd/news/sk-life-science-inc-to-present-new-data-and-epilepsy-insights-at-the-2026-american-academy-of-neurology-annual-meeting</guid>
<pubDate>Mon, 06 Apr 2026 12:04:00 GMT</pubDate>
<description>SK Life Science, Inc., a U.S. subsidiary of SK Biopharmaceuticals Co., Ltd., today announced that it will present multiple posters at the American Academy of Neurology (AAN)Annual Meeting, taking place April 18–22, 2026, in Chicago, Illinois.</description>
</item>
<item>
<title>SK Biopharmaceuticals Expands Radiopharmaceutical Therapy Portfolio with Second In-licensed Candidate from Wisconsin Alumni Research Foundation</title>
<link>https://6ix.com/company/sk-biopharmaceuticals-co-ltd/news/sk-biopharmaceuticals-expands-radiopharmaceutical-therapy-023900214</link>
<guid isPermaLink="true">https://6ix.com/company/sk-biopharmaceuticals-co-ltd/news/sk-biopharmaceuticals-expands-radiopharmaceutical-therapy-023900214</guid>
<pubDate>Thu, 27 Nov 2025 02:39:00 GMT</pubDate>
<description>SK Biopharmaceuticals, CO., Ltd., a biotech company specializing in research, development, and commercialization of treatments for central nervous system (CNS) disorders and oncology, announced a license agreement with the Wisconsin Alumni Research Foundation (WARF) to acquire the exclusive worldwide rights for research and development (R&D), manufacturing, and commercialization of WARF's "WT-7695," a preclinical-stage radiopharmaceutical therapy candidate developed in collaboration with the Uni</description>
</item>
<item>
<title>SK Life Science, Inc. to Present 10 Posters with New Cenobamate Data, Including a Late-Breaker, at the 2025 American Epilepsy Society (AES) Annual Meeting</title>
<link>https://6ix.com/company/sk-biopharmaceuticals-co-ltd/news/sk-life-science-inc-present-130400782</link>
<guid isPermaLink="true">https://6ix.com/company/sk-biopharmaceuticals-co-ltd/news/sk-life-science-inc-present-130400782</guid>
<pubDate>Fri, 21 Nov 2025 13:04:00 GMT</pubDate>
<description>SK Life Science, Inc., a global leader in treatments for central nervous system (CNS) disorders and a subsidiary of SK Biopharmaceuticals Co., Ltd., will present new data on cenobamate, an anti-seizure medication, at the 2025 American Epilepsy Society (AES) Annual Meeting in Atlanta, Georgia, December 5-9, 2025.</description>
</item>
<item>
<title>New SK Life Science, Inc. Survey Reveals Communication Gaps Between Patients and Providers That Can Impact Epilepsy Care Outcomes</title>
<link>https://6ix.com/company/sk-biopharmaceuticals-co-ltd/news/sk-life-science-inc-survey-155600310</link>
<guid isPermaLink="true">https://6ix.com/company/sk-biopharmaceuticals-co-ltd/news/sk-life-science-inc-survey-155600310</guid>
<pubDate>Tue, 28 Oct 2025 15:56:00 GMT</pubDate>
<description>As National Epilepsy Awareness Month begins on Saturday, new survey findings from SK Life Science, Inc., a global leader in treatments for central nervous system (CNS) disorders and a subsidiary of SK Biopharmaceuticals Co., Ltd., reveal striking communication gaps between patients and providers that can stand in the way of proper care and important treatment decisions. Notably, nearly three-quarters of people living with epilepsy report they don't share all seizures with their doctors, undersco</description>
</item>
<item>
<title>SK Life Science, Inc. to Host "Illuminating the Path to Added Seizure Reduction" Symposium at the 2025 American Epilepsy Society Annual Meeting</title>
<link>https://6ix.com/company/sk-biopharmaceuticals-co-ltd/news/sk-life-science-inc-host-135400135</link>
<guid isPermaLink="true">https://6ix.com/company/sk-biopharmaceuticals-co-ltd/news/sk-life-science-inc-host-135400135</guid>
<pubDate>Fri, 24 Oct 2025 13:54:00 GMT</pubDate>
<description>SK Life Science, Inc., a global leader in treatments for central nervous system (CNS) disorders and a subsidiary of SK Biopharmaceuticals Co., Ltd., today announced it will host an educational symposium led by world-renowned epileptologists during the 2025 American Epilepsy Society (AES) Annual Meeting in Atlanta, Georgia.</description>
</item>
<item>
<title>SK Biopharmaceuticals Launches Joint Venture with Eurofarma for AI-based Epilepsy Management Platform</title>
<link>https://6ix.com/company/sk-biopharmaceuticals-co-ltd/news/sk-biopharmaceuticals-launches-joint-venture-012000389</link>
<guid isPermaLink="true">https://6ix.com/company/sk-biopharmaceuticals-co-ltd/news/sk-biopharmaceuticals-launches-joint-venture-012000389</guid>
<pubDate>Tue, 21 Oct 2025 01:20:00 GMT</pubDate>
<description>SK Biopharmaceuticals, Co., Ltd., a biotech company focusing on research, development, and commercialization of treatments for disorders of the central nervous system (CNS) and oncology worldwide, today announced the establishment of Mentis Care, Inc., a joint venture with a leading Brazil-based pharmaceutical company, Eurofarma, with presence in 24 countries, including North America, Latin America and Africa, to commercialize an AI-based epilepsy management platform. The company hosted a launch</description>
</item>
</channel>
</rss>